JP2010539256A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010539256A5 JP2010539256A5 JP2010524314A JP2010524314A JP2010539256A5 JP 2010539256 A5 JP2010539256 A5 JP 2010539256A5 JP 2010524314 A JP2010524314 A JP 2010524314A JP 2010524314 A JP2010524314 A JP 2010524314A JP 2010539256 A5 JP2010539256 A5 JP 2010539256A5
- Authority
- JP
- Japan
- Prior art keywords
- cell surface
- polysaccharide
- surface polysaccharide
- mixture
- polysaccharides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000004676 glycans Chemical class 0.000 claims description 89
- 229920001282 polysaccharide Polymers 0.000 claims description 89
- 239000005017 polysaccharide Substances 0.000 claims description 89
- 210000004027 cell Anatomy 0.000 claims description 76
- 239000000203 mixture Substances 0.000 claims description 69
- 230000002163 immunogen Effects 0.000 claims description 27
- 241000193163 Clostridioides difficile Species 0.000 claims description 24
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 22
- 229960005486 vaccine Drugs 0.000 claims description 18
- 239000008103 glucose Substances 0.000 claims description 14
- -1 glycosyl phosphate Chemical compound 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 208000037384 Clostridium Infections Diseases 0.000 claims description 10
- 206010009657 Clostridium difficile colitis Diseases 0.000 claims description 10
- 206010054236 Clostridium difficile infection Diseases 0.000 claims description 10
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 10
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 10
- 206010012735 Diarrhoea Diseases 0.000 claims description 10
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 claims description 10
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 claims description 10
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims description 10
- 229910019142 PO4 Inorganic materials 0.000 claims description 10
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 10
- 230000028993 immune response Effects 0.000 claims description 10
- 230000001939 inductive effect Effects 0.000 claims description 9
- 239000010452 phosphate Substances 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- 239000003381 stabilizer Substances 0.000 claims description 6
- 241000588807 Bordetella Species 0.000 claims description 4
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 229960003983 diphtheria toxoid Drugs 0.000 claims description 4
- 230000003308 immunostimulating effect Effects 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 150000003214 pyranose derivatives Chemical class 0.000 claims description 4
- 229960000814 tetanus toxoid Drugs 0.000 claims description 4
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 claims description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 claims description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 claims description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 230000005847 immunogenicity Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 12
- 235000021317 phosphate Nutrition 0.000 description 5
- 238000010306 acid treatment Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97141107P | 2007-09-11 | 2007-09-11 | |
| US60/971,411 | 2007-09-11 | ||
| PCT/CA2008/001593 WO2009033268A1 (en) | 2007-09-11 | 2008-09-11 | Novel polysaccharide immunogens from clostridium difficile |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010539256A JP2010539256A (ja) | 2010-12-16 |
| JP2010539256A5 true JP2010539256A5 (enExample) | 2012-11-01 |
| JP5501969B2 JP5501969B2 (ja) | 2014-05-28 |
Family
ID=40451511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010524314A Active JP5501969B2 (ja) | 2007-09-11 | 2008-09-11 | クロストリジウム・ディフィシル由来の多糖免疫原 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8597663B2 (enExample) |
| EP (2) | EP2674169B1 (enExample) |
| JP (1) | JP5501969B2 (enExample) |
| CN (1) | CN101896197B (enExample) |
| AU (1) | AU2008299536B2 (enExample) |
| CA (2) | CA2941174C (enExample) |
| ES (2) | ES2528648T3 (enExample) |
| NZ (1) | NZ583750A (enExample) |
| WO (1) | WO2009033268A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008299536B2 (en) * | 2007-09-11 | 2014-06-12 | University Of Guelph | Novel polysaccharide immunogens from clostridium difficile |
| EP2655389A2 (en) * | 2010-12-24 | 2013-10-30 | Novartis AG | Compounds |
| CA2828374A1 (en) | 2011-03-08 | 2012-09-13 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Oligosaccharides and oligosaccharide-protein conjugates derived from clostridium difficile polysaccharide ps-ii, methods of synthesis and uses thereof, in particular as a vaccine |
| EP2554549A1 (en) | 2011-08-02 | 2013-02-06 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Oligosaccharides and oligosaccharides-protein conjugates derived from clostridium difficile polysaccharide PS-I, methods of synthesis and uses thereof, in particular as vaccines and diagnostic tools |
| US9815889B2 (en) | 2011-08-02 | 2017-11-14 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Antibodies for prevention and treatment of diseases caused by clostridium difficile |
| WO2013071409A1 (en) | 2011-11-18 | 2013-05-23 | National Research Council Of Canada (Nrc) | Clostridium difficile lipoteichoic acid and uses thereof |
| EP2872535A1 (en) | 2012-07-16 | 2015-05-20 | Pfizer Inc. | Saccharides and uses thereof |
| ES2672045T3 (es) * | 2014-07-25 | 2018-06-12 | Biosynth S.R.L. | Vacunas de productos glicoconjugados que comprenden unidades básicas de una construcción molecular que expresa múltiples epítopos incorporados para la formulación de una vacuna de amplio espectro contra infecciones debidas a bacterias enteropatógenas |
| CA3084847A1 (en) * | 2017-12-19 | 2019-06-27 | The Governors Of The University Of Alberta | Clostridium perfringens surface glycans and uses thereof |
| US10933126B2 (en) | 2018-05-03 | 2021-03-02 | The Board Of Regents Of The University Of Oklahoma | Clostridium difficile immunogenic compositions and methods of use |
| CN113329766A (zh) * | 2018-11-16 | 2021-08-31 | 马特里瓦克斯公司 | 艰难梭菌多组分疫苗 |
| US12187756B2 (en) | 2018-11-22 | 2025-01-07 | Idorsia Pharmaceuticals Ltd | Stable vaccine against Clostridium difficile |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
| CA1331443C (en) | 1987-05-29 | 1994-08-16 | Charlotte A. Kensil | Saponin adjuvant |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| US5562909A (en) | 1993-07-12 | 1996-10-08 | Massachusetts Institute Of Technology | Phosphazene polyelectrolytes as immunoadjuvants |
| GB9326174D0 (en) | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
| US20030072774A1 (en) | 1994-06-10 | 2003-04-17 | Diane M. Gajewczyk | Proteinaceous adjuvants |
| US6019982A (en) | 1994-08-26 | 2000-02-01 | The Administrators Of The Tulane Educational Fund | Mutant enterotoxin effective as a non-toxic oral adjuvant |
| FR2726764B1 (fr) | 1994-11-14 | 1997-01-31 | Pasteur Merieux Serums Vacc | Adjuvant pour composition vaccinale |
| US6284884B1 (en) | 1995-06-07 | 2001-09-04 | North American Vaccine, Inc. | Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof |
| WO1999055715A2 (en) | 1998-04-28 | 1999-11-04 | Galenica Pharmaceuticals, Inc. | Polysaccharide-antigen conjugates |
| GB0115176D0 (en) * | 2001-06-20 | 2001-08-15 | Chiron Spa | Capular polysaccharide solubilisation and combination vaccines |
| FI20011403A7 (fi) * | 2001-06-29 | 2002-12-30 | Carbion Oy | Menetelmä ja koostumukset vatsan sairauksien hoitoon |
| US7541043B2 (en) * | 2002-01-16 | 2009-06-02 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccine for protection against Shigella sonnei disease |
| WO2007038122A2 (en) | 2005-09-21 | 2007-04-05 | The United States Of America As Represented By The Secretary Of The Navy | Immunogenic capsule composition for use as a vaccine component against campylobacter jejuni |
| GB0713880D0 (en) * | 2007-07-17 | 2007-08-29 | Novartis Ag | Conjugate purification |
| AU2008299536B2 (en) * | 2007-09-11 | 2014-06-12 | University Of Guelph | Novel polysaccharide immunogens from clostridium difficile |
-
2008
- 2008-09-11 AU AU2008299536A patent/AU2008299536B2/en active Active
- 2008-09-11 EP EP13183746.0A patent/EP2674169B1/en active Active
- 2008-09-11 CA CA2941174A patent/CA2941174C/en active Active
- 2008-09-11 CA CA2698157A patent/CA2698157C/en active Active
- 2008-09-11 EP EP08800297.7A patent/EP2195018B1/en active Active
- 2008-09-11 ES ES08800297.7T patent/ES2528648T3/es active Active
- 2008-09-11 NZ NZ583750A patent/NZ583750A/en active IP Right Revival
- 2008-09-11 US US12/676,369 patent/US8597663B2/en active Active
- 2008-09-11 CN CN2008801155182A patent/CN101896197B/zh active Active
- 2008-09-11 WO PCT/CA2008/001593 patent/WO2009033268A1/en not_active Ceased
- 2008-09-11 JP JP2010524314A patent/JP5501969B2/ja active Active
- 2008-09-11 ES ES13183746.0T patent/ES2534671T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010539256A5 (enExample) | ||
| Barcelos et al. | Current status of biotechnological production and applications of microbial exopolysaccharides | |
| CN1154509C (zh) | 含有混合载体的多价疫苗组合物 | |
| CA2450203A1 (en) | Capsular polysaccharide solubilisation and combination vaccines | |
| AU2008299536B2 (en) | Novel polysaccharide immunogens from clostridium difficile | |
| RU2016127123A (ru) | Капсульные полисахариды Streptococcus pneumoniae и их конъюгаты | |
| RU2014134288A (ru) | Иммуногенная композиция | |
| JP2002528558A (ja) | 遺伝的に修飾されたグラム陰性細菌由来の低毒性ｌｐｓ | |
| TW200514569A (en) | Vaccine composition | |
| JP2011504487A5 (enExample) | ||
| US20240366743A1 (en) | Multivalent Pneumococcal Glycoconjugate Vaccines Containing Emerging Serotype 24F | |
| WO2014009971A3 (en) | Non-alcoholic vaccine compositions free from animal- origin and process for preparation thereof | |
| JP2011504535A5 (enExample) | ||
| KR20230164108A (ko) | E. coli O18 생물접합체의 생산 | |
| WO2023161817A1 (en) | Methods for incorporating azido groups in bacterial capsular polysaccharides | |
| JP2016513747A5 (enExample) | ||
| CN102626515B (zh) | b型流感嗜血杆菌多糖结合疫苗活化方法 | |
| KR102388325B1 (ko) | 저분자화 PRP를 사용한 Hib 컨쥬게이트 백신의 제조방법 | |
| CN101014698A (zh) | 作为多种疫苗候选物的保守性内核脂多糖表位 | |
| AU2018204255B2 (en) | Immunogenic composition against Campylobacter jejuni | |
| Compostella et al. | Antibacterial Carbohydrate Vaccines | |
| KR20200021933A (ko) | 나이세리아 메닌지티디스 혈청군 x 캡슐 다당류의 급속 고수율 정제 방법 | |
| HUP0700044A2 (en) | Conserved inner core lipopolysaccharide epitopes as multi-species vaccine candidates | |
| RU2429292C1 (ru) | РЕКОМБИНАНТНАЯ ПЛАЗМИДА pAg85A-CBD, ШТАММ Escherichia coli [pREP4, pAg85A-CBD], ХИМЕРНЫЙ БЕЛОК Ag85A-CBD И ИХ ПРИМЕНЕНИЕ | |
| RU2636454C2 (ru) | Вакцина для профилактики некробактериоза животных и способ её получения |